Handsfield H H
Sex Transm Dis. 1986 Jul-Sep;13(3 Suppl):179-84. doi: 10.1097/00007435-198607000-00017.
Despite the development of many antimicrobial drugs that are active against sexually transmitted bacterial pathogens, various problems limit the success of treatment of bacterial sexually transmitted diseases (STD). These problems include the evolution and spread of antibiotic-resistant pathogens, inconsistent therapeutic efficacy of some regimens despite in-vitro activity against the infecting organism, toxicity, inconvenience of administration, lack of compliance by patients, and cost. Diseases affected by one or more of these therapeutic problems include gonorrhea, chlamydial infections, pelvic inflammatory disease, bacterial vaginosis, syphilis, and chancroid. Ceftriaxone, a new cephalosporin, addresses some of these problems as they relate to gonorrhea, chancroid, and, possibly, syphilis.
尽管已研发出许多对性传播细菌病原体有效的抗菌药物，但各种问题限制了细菌性传播疾病（STD）治疗的成功率。这些问题包括抗生素耐药病原体的演变和传播、某些治疗方案尽管在体外对感染病原体有活性但其治疗效果不一致、毒性、给药不便、患者依从性差以及成本问题。受这些治疗问题中一个或多个影响的疾病包括淋病、衣原体感染、盆腔炎、细菌性阴道病、梅毒和软下疳。新型头孢菌素头孢曲松解决了其中一些与淋病、软下疳以及可能与梅毒相关的问题。
